The invention relates to the technical field of medicines, in particular to application of cirsimaritin in preparing an
antiviral drug. The invention for the first time proposes that the cirsimaritin has definite resistance to an influenza
virus. The cirsimaritin can significantly inhibit a
cytopathic effect caused by the influenza
virus infection, and median inhibitory concentrations to an influenza
virus A / FortMonmouth / 1 / 1947 and an influenza virus A / jinnan / 15 / 2009 are equivalent to that of an influenza virus
Amantadine and an influenza virus
Ribavirin; meanwhile, the cirsimaritin can significantly inhibit the expression of influenza virus
specific protein M2
protein, and lower an expression level of
influenza virus RNA; the intensities of inhibition functions of 40 microgrammes per milliliter of the cirsimaritin on expression of the influenza virus M2
protein and expression of the
influenza virus RNA are equivalent to that of 10 micrometers of the
Ribavirin, showing that intensity of the anti-influenza virus effect of the cirsimaritin is close to that of antiviral drugs currently commonly used in clinic, and application of the cirsimaritin in preparing anti-influenza drugs has a good prospect.